 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Growth factor
|
PDB id
|
|
|
|
1fga
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Biochemical function
|
growth factor activity
|
1 term
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
Protein Sci
2:1274-1284
(1993)
|
|
PubMed id:
|
|
|
|
|
| |
|
Refinement of the structure of human basic fibroblast growth factor at 1.6 A resolution and analysis of presumed heparin binding sites by selenate substitution.
|
|
A.E.Eriksson,
L.S.Cousens,
B.W.Matthews.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The three-dimensional structure of human basic fibroblast growth factor has been
refined to a crystallographic residual of 16.1% at 1.6 A resolution. The
structure has a Kunitz-type fold and is composed of 12 antiparallel
beta-strands, 6 of which form a beta-barrel. One bound sulfate ion has been
identified in the model, hydrogen bonded to the side chains of Asn 27, Arg 120,
and Lys 125. The side chain of Arg 120 has two conformations, both of which
permit hydrogen bonds to the sulfate. This sulfate binding site has been
suggested as the binding site for heparin (Eriksson, A.E., Cousens, L.S.,
Weaver, L.H., & Matthews, B.W., 1991, Proc. Natl. Acad. Sci. USA 88,
3441-3445). Two beta-mercaptoethanol (BME) molecules are also included in the
model, each forming a disulfide bond to the S gamma atoms of Cys 69 and Cys 92,
respectively. The side chain of Cys 92 has two conformations of which only one
can bind BME. Therefore the BME molecule is half occupied at this site. The
locations of possible sulfate binding sites on the protein were examined by
replacing the ammonium sulfate in the crystallization medium with ammonium
selenate. Diffraction data were measured to 2.2 A resolution and the structure
refined to an R-factor of 13.8%. The binding of the more electron-dense selenate
ion was identified at two positions. One position was identical to the sulfate
binding site identified previously. The second selenate binding site, which is
of lower occupancy, is situated 5.6 A from the first. This ion is hydrogen
bonded by the side chain of Lys 135 and Arg 120. Thus the side chain of Arg 120
binds two selenate ions simultaneously. It is suggested that the observed second
selenate binding site should also be considered as a possible binding site for
heparin, or that both selenate binding sites might simultaneously contribute to
the binding of heparin.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Fig. 3. lignmentoftheamioacidsequencesofhbFGFAbrahametal., 1986) (sequencenumberedtocorrespondtobovine
bFGF; Eschet l., 1985) andinterleukin(IL)-Ip(Gimenez-Gallegoetal., 1985; Thomas Gimenez-Gallego, 1986) suggested
bythecorrespondencebetweentheirthree-dimesionalcrystalstructures(Priestleeal., 1989; Erikssonetal., 1991; thiswork).
TesequeneofbovineaFGF is alsoincluded(Gimenez-Gallegoetal., 1985). The50residueswhoseor-carbonsstructurallysu-
perimposewith anrmsdiscrepancyof0.52 A areindicatedwithasterisks.ResiduesinbFGFthatareindicatedbythealgorithm
ofKabschandSanders (1983) ashavinga&sheetconformationareindicated (0). Thereare IO uch ''&sheet strandsshown
inthefigue.Therearetwadditionalsegmnts,indicated 0 . . . ) thatdonot fulfilltheKabschandSanderscriteiafor
0-sheetstrandsbutformthe10thand1lth of the 2 @-strandsthatcomprisetheoverallframework of thebFGFandIL-10struc-
tures.Thesesegmentshavebeenrealignedrelative to Erikssonetal. (1991) o nowcompriseresidues 115-117 and 122-127.
|
 |
Figure 5.
Fig. 5. Schematicdrawingillustratingthebindingoftwoselenateions
tohbFGF.ConventionsasinFigure .
|
 |
|
|
|
| |
The above figures are
reprinted
from an Open Access publication published by the Protein Society:
Protein Sci
(1993,
2,
1274-1284)
copyright 1993.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
I.S.Fernández,
P.Cuevas,
J.Angulo,
P.López-Navajas,
A.Canales-Mayordomo,
R.González-Corrochano,
R.M.Lozano,
S.Valverde,
J.Jiménez-Barbero,
A.Romero,
and
G.Giménez-Gallego
(2010).
Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors.
|
| |
J Biol Chem, 285,
11714-11729.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
O.Alsmadi,
B.F.Meyer,
F.Alkuraya,
S.Wakil,
F.Alkayal,
H.Al-Saud,
K.Ramzan,
and
M.Al-Sayed
(2009).
Syndromic congenital sensorineural deafness, microtia and microdontia resulting from a novel homoallelic mutation in fibroblast growth factor 3 (FGF3).
|
| |
Eur J Hum Genet, 17,
14-21.
|
 |
|
|
|
|
 |
H.Yin,
and
A.D.Hamilton
(2005).
Strategies for targeting protein-protein interactions with synthetic agents.
|
| |
Angew Chem Int Ed Engl, 44,
4130-4163.
|
 |
|
|
|
|
 |
Q.Wu,
J.Wang,
L.Zhang,
A.Hong,
and
J.Ren
(2005).
Molecular recognition of basic fibroblast growth factor by polyoxometalates.
|
| |
Angew Chem Int Ed Engl, 44,
4048-4052.
|
 |
|
|
|
|
 |
M.Zamai,
C.Hariharan,
D.Pines,
M.Safran,
A.Yayon,
V.R.Caiolfa,
R.Cohen-Luria,
E.Pines,
and
A.H.Parola
(2002).
Nature of Interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino])-bis-(1,3-naphtalene disulfonate). II. Removal of polar interactions affects protein folding.
|
| |
Biophys J, 82,
2652-2664.
|
 |
|
|
|
|
 |
M.M.Young,
N.Tang,
J.C.Hempel,
C.M.Oshiro,
E.W.Taylor,
I.D.Kuntz,
B.W.Gibson,
and
G.Dollinger
(2000).
High throughput protein fold identification by using experimental constraints derived from intramolecular cross-links and mass spectrometry.
|
| |
Proc Natl Acad Sci U S A, 97,
5802-5806.
|
 |
|
|
|
|
 |
Z.Dauter,
M.Dauter,
and
K.R.Rajashankar
(2000).
Novel approach to phasing proteins: derivatization by short cryo-soaking with halides.
|
| |
Acta Crystallogr D Biol Crystallogr, 56,
232-237.
|
 |
|
|
|
|
 |
G.Venkataraman,
R.Raman,
V.Sasisekharan,
and
R.Sasisekharan
(1999).
Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex.
|
| |
Proc Natl Acad Sci U S A, 96,
3658-3663.
|
 |
|
|
|
|
 |
G.Venkataraman,
Z.Shriver,
J.C.Davis,
and
R.Sasisekharan
(1999).
Fibroblast growth factors 1 and 2 are distinct in oligomerization in the presence of heparin-like glycosaminoglycans.
|
| |
Proc Natl Acad Sci U S A, 96,
1892-1897.
|
 |
|
|
|
|
 |
W.J.LaRochelle,
K.Sakaguchi,
N.Atabey,
H.G.Cheon,
Y.Takagi,
T.Kinaia,
R.M.Day,
T.Miki,
W.H.Burgess,
and
D.P.Bottaro
(1999).
Heparan sulfate proteoglycan modulates keratinocyte growth factor signaling through interaction with both ligand and receptor.
|
| |
Biochemistry, 38,
1765-1771.
|
 |
|
|
|
|
 |
Y.P.Nieh,
and
K.Y.Zhang
(1999).
A two-dimensional histogram-matching method for protein phase refinement and extension.
|
| |
Acta Crystallogr D Biol Crystallogr, 55,
1893-1900.
|
 |
|
|
|
|
 |
M.Zamai,
V.R.Caiolfa,
D.Pines,
E.Pines,
and
A.H.Parola
(1998).
Nature of interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(Carbonyl-bis[imino-N-methyl-4, 2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino] )bis-(1, 3-naphthalene disulfonate).
|
| |
Biophys J, 75,
672-682.
|
 |
|
|
|
|
 |
P.J.Kim,
K.Sakaguchi,
H.Sakamoto,
C.Saxinger,
R.Day,
P.McPhie,
J.S.Rubin,
and
D.P.Bottaro
(1998).
Colocalization of heparin and receptor binding sites on keratinocyte growth factor.
|
| |
Biochemistry, 37,
8853-8862.
|
 |
|
|
|
|
 |
F.J.Moy,
M.Safran,
A.P.Seddon,
D.Kitchen,
P.Böhlen,
D.Aviezer,
A.Yayon,
and
R.Powers
(1997).
Properly oriented heparin-decasaccharide-induced dimers are the biologically active form of basic fibroblast growth factor.
|
| |
Biochemistry, 36,
4782-4791.
|
 |
|
|
|
|
 |
A.Krufka,
S.Guimond,
and
A.C.Rapraeger
(1996).
Two hierarchies of FGF-2 signaling in heparin: mitogenic stimulation and high-affinity binding/receptor transphosphorylation.
|
| |
Biochemistry, 35,
11131-11141.
|
 |
|
|
|
|
 |
F.J.Moy,
A.P.Seddon,
P.Böhlen,
and
R.Powers
(1996).
High-resolution solution structure of basic fibroblast growth factor determined by multidimensional heteronuclear magnetic resonance spectroscopy.
|
| |
Biochemistry, 35,
13552-13561.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
G.Venkataraman,
V.Sasisekharan,
A.B.Herr,
D.M.Ornitz,
G.Waksman,
C.L.Cooney,
R.Langer,
and
R.Sasisekharan
(1996).
Preferential self-association of basic fibroblast growth factor is stabilized by heparin during receptor dimerization and activation.
|
| |
Proc Natl Acad Sci U S A, 93,
845-850.
|
 |
|
|
|
|
 |
M.Blaber,
J.DiSalvo,
and
K.A.Thomas
(1996).
X-ray crystal structure of human acidic fibroblast growth factor.
|
| |
Biochemistry, 35,
2086-2094.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.C.Rapraeger
(1995).
In the clutches of proteoglycans: how does heparan sulfate regulate FGF binding?
|
| |
Chem Biol, 2,
645-649.
|
 |
|
|
|
|
 |
D.B.Volkin,
A.M.Verticelli,
M.W.Bruner,
K.E.Marfia,
P.K.Tsai,
M.K.Sardana,
and
C.R.Middaugh
(1995).
Deamidation of polyanion-stabilized acidic fibroblast growth factor.
|
| |
J Pharm Sci, 84,
7.
|
 |
|
|
|
|
 |
A.D.Lander
(1994).
Targeting the glycosaminoglycan-binding sites on proteins.
|
| |
Chem Biol, 1,
73-78.
|
 |
|
|
|
|
 |
P.Pjura,
M.Matsumura,
W.A.Baase,
and
B.W.Matthews
(1993).
Development of an in vivo method to identify mutants of phage T4 lysozyme of enhanced thermostability.
|
| |
Protein Sci, 2,
2217-2225.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|